Sarepta Therapeutics(SRPT)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

SRPT Sarepta Therapeutics

交易中 05-29 09:53:08 EDT

113.86

+0.53

+0.46%

最高114.23	最低112.98	成交量5.12万
今开113.46	昨收113.33	日振幅1.10%
总市值107.62亿	流通市值102.83亿	总股本9,452万
成交额582.12万	换手率0.06%	流通股本9,032万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"SRPT","market":"US","secType":"STK","nameCN":"Sarepta Therapeutics","latestPrice":113.855,"timestamp":1716990788676,"preClose":113.33,"halted":0,"volume":51199,"delay":0,"floatShares":90316352,"shares":94523766,"eps":0.180044,"marketStatus":"交易中","marketStatusCode":2,"change":0.525,"latestTime":"05-29 09:53:08 EDT","open":113.46,"high":114.2265,"low":112.975,"amount":5821183.96678,"amplitude":0.011043,"askPrice":113.97,"askSize":138,"bidPrice":113.74,"bidSize":157,"shortable":0,"etf":0,"ttmEps":0.180044,"exchange":"NASDAQ","tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1717012800000},"adr":0,"listingDate":865396800000,"adjPreClose":113.33,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":113.32,"preClose":113.33,"latestTime":"09:29 EDT","volume":116,"amount":13151.84916,"timestamp":1716989399999},"postHourTrading":{"tag":"盘后","latestPrice":114.99,"preClose":113.33,"latestTime":"19:43 EDT","volume":120854,"amount":13728386.327,"timestamp":1716939806573},"volumeRatio":0.65714},"requestUrl":"/m/hq/s/SRPT/","defaultTab":"news","newsList":[{"id":"2439130476","title":"BUZZ-在加拿大皇家银行将 Sarepta 的评级下调至 \"行业表现 \"并下调预期收益率后，该公司股价下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2439130476","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2439130476?lang=zh_cn&edition=full","pubTime":"2024-05-29 00:02","pubTimestamp":1716912146,"startTime":"0","endTime":"0","summary":"** 美国食品和药物管理局 预计将在 6 月 21 日前就 SRPT 为其肌肉萎缩症基因疗法 Elevidys申请传统批准做出决定。** 该申请要求在使用该疗法时不受年龄和行走能力的限制** 在过去几周里，我们与投资者进行了广泛的讨论，目前公司股价在过去六个月里上涨了 50%，我们认为投资者对 FDA 就 Elevidys 标签做出决定的预期已经大大增加。** 我们感觉 FDA 和公司发出的信息略有缓和 - 经纪公司** 年初至今，股价上涨了 15","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2438370392","title":"Sarepta Therapeutics, Inc.盘中异动 快速下挫5.05%报117.23美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2438370392","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2438370392?lang=zh_cn&edition=full","pubTime":"2024-05-28 21:33","pubTimestamp":1716903191,"startTime":"0","endTime":"0","summary":"北京时间2024年05月28日21时33分，Sarepta Therapeutics, Inc.股票出现异动，股价快速下挫5.05%。Sarepta Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.86%。Sarepta Therapeutics, Inc.公司简介：Sarepta Therapeutics公司是一家专注于治疗罕见、传染病和其他疾病的生物技术公司。该信息摘要如下：Sarepta Therapeutics Inc：加拿大皇家银行从跑赢大盘下调行业表现；将目标价从157美元下调至142美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240528213311968103c2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240528213311968103c2&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2438985321","title":"Sarepta Therapeutics Inc：加拿大皇家银行从跑赢大盘下调行业表现；将目标价从157美元下调至142美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2438985321","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2438985321?lang=zh_cn&edition=full","pubTime":"2024-05-28 18:37","pubTimestamp":1716892660,"startTime":"0","endTime":"0","summary":"Sarepta Therapeutics Inc：加拿大皇家银行从跑赢大盘下调行业表现；将目标价从157美元下调至142美元","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240528183744956e5bd2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240528183744956e5bd2&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2436761471","title":"Needham：重申Sarepta Therapeutics(SRPT.US)评级，由买入调整至买入评级, 目标价166.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2436761471","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2436761471?lang=zh_cn&edition=full","pubTime":"2024-05-20 18:35","pubTimestamp":1716201341,"startTime":"0","endTime":"0","summary":"Needham：重申Sarepta Therapeutics(SRPT.US)评级，由买入调整至买入评级, 目标价166.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405201835468b1b39b1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405201835468b1b39b1&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2436969363","title":"美国研究综述-迪尔公司、Under Armour、沃尔玛","url":"https://stock-news.laohu8.com/highlight/detail?id=2436969363","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2436969363?lang=zh_cn&edition=full","pubTime":"2024-05-17 14:56","pubTimestamp":1715928964,"startTime":"0","endTime":"0","summary":"    路透5月17日 - 华尔街证券分析师周五调整了对几家美国上市公司的评级和目标价，其中包括迪尔公司、Under Armour 和沃尔玛。要闻              * Advanced Drainage Systems Inc   ：巴克莱将其目标价从189美元上调至202美元             * 迪尔公司  ：大和资本市场将目标价从400美元上调至440美元             * Under Armour Inc   ：摩根大通将其评级从 \"中性 \"下调至 \"减持\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2433276434","title":"Sarepta Therapeutics, Inc.2024财年第一财季实现净利润36.12百万美元，同比增加106.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2433276434","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2433276434?lang=zh_cn&edition=full","pubTime":"2024-05-06 00:25","pubTimestamp":1714926301,"startTime":"0","endTime":"0","summary":"3月31日，Sarepta Therapeutics, Inc.公布财报，公告显示公司2024财年第一财季净利润为36.12百万美元，同比增加106.99%；其中营业收入为4.13亿美元，同比增加62.60%，每股基本收益为0.38美元。从资产负债表来看，Sarepta Therapeutics, Inc.总负债22.63亿美元，其中短期债务1.06亿美元，资产负债比为1.43，流动比率为4.05。机构评级：截至2024年3月31日，当前有19家机构对Sarepta Therapeutics, Inc.目标价做出预测，其中目标均价为166.89美元，其中最低目标价为128.00美元，最高目标价为224.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050600250487d52c4f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050600250487d52c4f&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2432635946","title":"美国研究综述-Paramount Global、Sprout Social、Williams-Sonoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2432635946","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2432635946?lang=zh_cn&edition=full","pubTime":"2024-05-03 15:04","pubTimestamp":1714719854,"startTime":"0","endTime":"0","summary":"    路透5月3日 - 华尔街证券分析师周五调整了对派拉蒙全球公司、Sprout Social 和 Williams-Sonoma 等几家美国上市公司的评级和目标价。* Paramount Global   ：Seaport Research Partners将其评级从 \"买入 \"下调至 \"中性\"。* Williams-Sonoma Inc   ：摩根大通将其评级从 \"减持 \"上调至 \"中性\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2432298261","title":"坎托菲茨杰拉德公司：重申Sarepta Therapeutics(SRPT.US)评级，由中性调整至中性评级, 目标价128.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2432298261","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2432298261?lang=zh_cn&edition=full","pubTime":"2024-05-03 00:25","pubTimestamp":1714667111,"startTime":"0","endTime":"0","summary":"坎托菲茨杰拉德公司：重申Sarepta Therapeutics(SRPT.US)评级，由中性调整至中性评级, 目标价128.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050300251487cb8791&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050300251487cb8791&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2432601002","title":"BUZZ-Sarepta 第一季度营收超预期后上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2432601002","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2432601002?lang=zh_cn&edition=full","pubTime":"2024-05-02 21:49","pubTimestamp":1714657754,"startTime":"0","endTime":"0","summary":"    5月2日 - ** Sarepta Therapeutics公司  股价上涨7%，达到两个月来的最高点140.10美元。** 该公司周三公布的  第一季度营收为 4.135 亿美元，预计为 3.778 亿美元 - LSEG** 公司表示，在监管机构决定扩大该疗法的患者范围之前，美国食品及药物管理局将比之前预计的更早向公司提供其基因疗法Elevidys的标签草案，该疗法用于治疗一种肌肉萎缩疾病。** FDA对Elevidys的目标行动日期是6月21日** 经纪公司 BMO Capital Markets 认为，FDA 对 Elevidys 的决定 \"很可能在 6 月初公布\"。** 年初至今，股价上涨了 47.1%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2432160967","title":"Sarepta Therapeutics, Inc.盘中异动 早盘大幅拉升8.10%报141.50美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2432160967","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2432160967?lang=zh_cn&edition=full","pubTime":"2024-05-02 21:32","pubTimestamp":1714656731,"startTime":"0","endTime":"0","summary":"北京时间2024年05月02日21时32分，Sarepta Therapeutics, Inc.股票出现波动，股价快速拉升8.10%。Sarepta Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.24%。其相关个股中，Allarity Therapeutics, Inc.、Context Therapeutics Inc.、Aptevo Therapeutics Inc.涨幅较大，Allarity Therapeutics, Inc.、Aptevo Therapeutics Inc.、Context Therapeutics Inc.较为活跃，换手率分别为1438.68%、301.14%、82.61%，振幅较大的相关个股有Allarity Therapeutics, Inc.、Zura Bio Limited C/Wts 、Aptevo Therapeutics Inc.，振幅分别为30.66%、22.07%、11.47%。Sarepta Therapeutics, Inc.公司简介：Sarepta Therapeutics公司是一家专注于治疗罕见、传染病和其他疾病的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405022132118b6d288c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405022132118b6d288c&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2416909567","title":"Sarepta Therapeutics, Inc.2023财年实现净利润-5.36亿美元，同比增加23.76%","url":"https://stock-news.laohu8.com/highlight/detail?id=2416909567","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2416909567?lang=zh_cn&edition=full","pubTime":"2024-03-04 00:27","pubTimestamp":1709483234,"startTime":"0","endTime":"0","summary":"12月31日，Sarepta Therapeutics, Inc.公布财报，公告显示公司2023财年净利润为-5.36亿美元，同比增加23.76%；其中营业收入为12.43亿美元，同比增加33.23%，每股基本收益为-5.80美元。机构评级：截至2023年12月31日，当前有21家机构对Sarepta Therapeutics, Inc.目标价做出预测，其中目标均价为164.42美元，其中最低目标价为128.00美元，最高目标价为224.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024030400272887e0e75a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024030400272887e0e75a&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2416521498","title":"Sarepta Therapeutics, Inc.盘中异动 早盘股价大跌5.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2416521498","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2416521498?lang=zh_cn&edition=full","pubTime":"2024-02-29 22:58","pubTimestamp":1709218733,"startTime":"0","endTime":"0","summary":"北京时间2024年02月29日22时58分，Sarepta Therapeutics, Inc.股票出现异动，股价急速跳水5.23%。Sarepta Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为1.28%。Sarepta Therapeutics, Inc.公司简介：Sarepta Therapeutics Inc 是一家专注于治疗罕见病、传染病和其他疾病的生物技术公司。Sarepta 的战略涉及专有的 RNA 靶向技术平台，用于开发新型药物产品以治疗广泛的疾病并解决关键的未满足医疗需求。Sarepta 的大多数候选产品都处于开发的早期阶段。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024022922585387e74e92&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024022922585387e74e92&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2415056730","title":"美国研究综述-Okta、Salesforce、Sarepta Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2415056730","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2415056730?lang=zh_cn&edition=full","pubTime":"2024-02-29 15:07","pubTimestamp":1709190420,"startTime":"0","endTime":"0","summary":"    路透社2月29日 - 华尔街证券分析师周四调整了对几家美国上市公司的评级和目标价，其中包括 Okta、Salesforce 和 Sarepta Therapeutics。要点             * Clearwater Analytics Holdings Inc   ：摩根大通将其评级从 \"增持 \"下调至 \"中性             * Okta Inc   ：Piper Sandler将目标价从85美元上调至110美元              * Salesforce Inc   ：巴克莱将目标价从325美元上调至355美元              * Sarepta Therapeutics Inc   ：Leerink Partners将目标价从145美元上调至165美元              * Universal Health Services Inc   ：Leerink Partners将目标价从174美元上调至192美元  以下是路透社周四报道的美国公司研究行动摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2414616128","title":"Sarepta Therapeutics Inc   预计每股收益1美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2414616128","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2414616128?lang=zh_cn&edition=full","pubTime":"2024-02-27 07:09","pubTimestamp":1708988955,"startTime":"0","endTime":"0","summary":"   * Sarepta Therapeutics Inc    将于2月28日公布截至2023年12月31日的财报，预计该公司的季度收入将有所增长。* 根据LSEG的数据，16位分析师的平均预期显示，这家总部位于马萨诸塞州剑桥市的公司预计将实现49.5%的营收增长，从去年同期的2.5843亿美元增至3.863亿美元。* LSEG 分析师对 Sarepta Therapeutics Inc 的平均预期为每股收益 1 美分。* 华尔街对 Sarepta Therapeutics Inc 的 12 个月目标价中位数为 160.00 美元，高于其最后收盘价 136.53 美元。2月26日 - 上一季度业绩。除非另有说明，否则所有数据均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2413759544","title":"分析-2023 年美国新药价格同比上涨 35","url":"https://stock-news.laohu8.com/highlight/detail?id=2413759544","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2413759544?lang=zh_cn&edition=full","pubTime":"2024-02-23 19:00","pubTimestamp":1708686011,"startTime":"0","endTime":"0","summary":" Deena Beasley    路透社2月23日 - 路透社的一项分析发现，制药公司去年推出的美国新药价格比2022年高出35%，这在一定程度上反映了该行业对肌肉萎缩症等罕见疾病昂贵疗法的追捧。根据路透社对47种药品的分析，2023年新药 ，年上市价格中位数为30万美元，高于一年前的22.2万美元 。路透社分析了 FDA 去年批准的 55 种新型药物，高于 2022 年的 37 种。根据美国政府的数据，在截至 12 月的 12 个月中，处方药价格的通胀率为 3.3%，与总体通胀率基本持平。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2412972660","title":"美国研究综述-欧特克、Hireright Holdings、斑马技术公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2412972660","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2412972660?lang=zh_cn&edition=full","pubTime":"2024-02-19 14:40","pubTimestamp":1708324852,"startTime":"0","endTime":"0","summary":"    路透社2月19日 - 华尔街证券分析师周一调整了对几家美国上市公司的评级和目标价，其中包括 Autodesk、Hireright Holdings 和斑马技术公司。要闻             * 欧特克公司  ：贝伦贝格将目标价从250美元上调至290美元              * Hireright Holdings Corp   ：Needham将目标价从 \"买入 \"下调至 \"持有              * 斑马技术公司  ：Baird将目标价从292美元上调至312美元  以下是路透社周一报道的美国公司研究报告摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2411566281","title":"嗡嗡声--美国股票走势-Super Micro Computer、Kinsale Capital、Kinnate Biopharma","url":"https://stock-news.laohu8.com/highlight/detail?id=2411566281","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2411566281?lang=zh_cn&edition=full","pubTime":"2024-02-16 23:53","pubTimestamp":1708098808,"startTime":"0","endTime":"0","summary":"        *      个股异动的 Eikon 搜索字符串：[STXBZ］        *      The Day Ahead 新闻通讯：          *      The Morning News Call时事通讯：      2月16日 - 周五，华尔街主要股指走低，此前一份热度高于预期的生产者物价报告打压了市场对美国联邦储备委员会  即将降息的猜测。美东时间10:31，道琼斯工业平均指数  下跌0.27%，报38,669.2点。标准普尔500指数  下跌0.39%，报5,010.17点；纳斯达克综合指数  下跌0.75%，报15,787.267点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2411666726","title":"Sarepta Therapeutics Inc盘中异动 早盘大幅拉升12.78%报140.85美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2411666726","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2411666726?lang=zh_cn&edition=full","pubTime":"2024-02-16 22:31","pubTimestamp":1708093861,"startTime":"0","endTime":"0","summary":"北京时间2024年02月16日22时31分，Sarepta Therapeutics Inc股票出现异动，股价快速上涨12.78%。Sarepta Therapeutics Inc股票所在的生物技术行业中，整体跌幅为0.01%。Sarepta Therapeutics Inc公司简介：Sarepta Therapeutics Inc 是一家专注于治疗罕见病、传染病和其他疾病的生物技术公司。Sarepta 的战略涉及专有的 RNA 靶向技术平台，用于开发新型药物产品以治疗广泛的疾病并解决关键的未满足医疗需求。Sarepta 的大多数候选产品都处于开发的早期阶段。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202402162231018192be23&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202402162231018192be23&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2411500886","title":"更新版 2-更正-美国 FDA 将审查 Sarepta 公司的杜兴氏基因疗法能否获得传统批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2411500886","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2411500886?lang=zh_cn&edition=full","pubTime":"2024-02-16 21:46","pubTimestamp":1708091211,"startTime":"0","endTime":"0","summary":"根据一项中期试验，该基因疗法产生了一种帮助保持肌肉完整所需的迷你版肌营养不良蛋白，最初批准的对象是4至5岁能行走的儿童。去年5月，   ，在讨论加速审批时，一些 专家组成员曾表示，Sarepta公司为证实基因疗法的益处而进行的后期试验将具有影响力。除了传统的审批外，Sarepta 公司的申请还要求取消对使用基因疗法的年龄和行走能力的限制。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sarepta.com","stockEarnings":[{"period":"1week","weight":-0.1223},{"period":"1month","weight":-0.1199},{"period":"3month","weight":-0.1758},{"period":"6month","weight":0.3943},{"period":"1year","weight":-0.1064},{"period":"ytd","weight":0.1753}],"compareEarnings":[{"period":"1week","weight":-0.0029},{"period":"1month","weight":0.0424},{"period":"3month","weight":0.0465},{"period":"6month","weight":0.1608},{"period":"1year","weight":0.2614},{"period":"ytd","weight":0.1147}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Sarepta Therapeutics, Inc.于1980年7月22日在俄勒冈州注册成立。该公司是一家商业阶段的生物制药公司，专注于通过发现和开发独特的RNA靶向疗法、基因疗法和其他用于治疗罕见疾病的基因治疗模式来帮助患者。应用他们的专有、高度差异化和创新技术，并通过与战略合作伙伴的合作，该公司开发了多个获批产品，用于治疗杜氏肌营养不良症，并正在为广泛的疾病和紊乱开发潜在的候选治疗药物，包括杜氏、肢带型肌营养不良症和其他与神经肌肉和中枢神经系统相关的疾病。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.050901},{"month":2,"riseRate":0.666667,"avgChangeRate":0.055118},{"month":3,"riseRate":0.5,"avgChangeRate":0.024789},{"month":4,"riseRate":0.333333,"avgChangeRate":0.013657},{"month":5,"riseRate":0.666667,"avgChangeRate":0.166082},{"month":6,"riseRate":0.727273,"avgChangeRate":0.088071},{"month":7,"riseRate":0.363636,"avgChangeRate":0.007489},{"month":8,"riseRate":0.75,"avgChangeRate":0.094027},{"month":9,"riseRate":0.583333,"avgChangeRate":0.152276},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.101643},{"month":11,"riseRate":0.75,"avgChangeRate":0.091344},{"month":12,"riseRate":0.583333,"avgChangeRate":0.019375}],"exchange":"NASDAQ","name":"Sarepta Therapeutics","nameEN":"Sarepta Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Sarepta Therapeutics(SRPT)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Sarepta Therapeutics(SRPT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Sarepta Therapeutics,SRPT,Sarepta Therapeutics股票,Sarepta Therapeutics股票老虎,Sarepta Therapeutics股票老虎国际,Sarepta Therapeutics行情,Sarepta Therapeutics股票行情,Sarepta Therapeutics股价,Sarepta Therapeutics股市,Sarepta Therapeutics股票价格,Sarepta Therapeutics股票交易,Sarepta Therapeutics股票购买,Sarepta Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Sarepta Therapeutics(SRPT)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Sarepta Therapeutics(SRPT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}